adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.
Company profile
Ticker
ADIL
Exchange
Website
CEO
William B. Stilley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADial Pharmaceuticals, L.L.C., Adial Pharmaceuticals, L.L.C.
SEC CIK
Corporate docs
Subsidiaries
Purnovate, Inc. ...
IRS number
800667150
ADIL stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
18 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
S-3
Shelf registration
12 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
D
$287.50 k in equity / options / securities to be acquired, sold $287.50 k, 1 investor
14 Mar 24
8-K
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
6 Mar 24
424B5
Prospectus supplement for primary offering
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
Latest ownership filings
4
Robertson H. Gilliland
27 Mar 24
4
James W. Jr. Newman
27 Mar 24
4
Joseph Truluck
27 Mar 24
4
Cary J Claiborne
27 Mar 24
4
J. Kermit Anderson
27 Mar 24
4
Kevin Schuyler
27 Mar 24
4
Tony Goodman
27 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Kevin Schuyler
3 Oct 23
4
Bankole A. Johnson
2 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 315.88 k | 315.88 k | 315.88 k | 315.88 k | 315.88 k | 315.88 k |
Cash burn (monthly) | 300.78 k | 453.07 k | 452.65 k | 903.64 k | 463.67 k | 611.26 k |
Cash used (since last report) | 2.01 mm | 3.02 mm | 3.02 mm | 6.02 mm | 3.09 mm | 4.08 mm |
Cash remaining | -1.69 mm | -2.70 mm | -2.70 mm | -5.71 mm | -2.78 mm | -3.76 mm |
Runway (months of cash) | -5.6 | -6.0 | -6.0 | -6.3 | -6.0 | -6.2 |
Institutional ownership, Q2 2023
74.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 443.10 mm |
Total shares | 3.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Manchester Capital Management | 1.20 mm | $250.35 mm |
Schuyler Kevin | 673.60 k | $1.47 mm |
Vanguard | 203.36 k | $42.34 mm |
BLK Blackrock | 194.36 k | $40.47 mm |
Susquehanna International | 180.29 k | $37.50 mm |
Geode Capital Management | 137.46 k | $28.59 mm |
Renaissance Technologies | 107.10 k | $22.00 k |
STT State Street | 52.35 k | $10.89 mm |
Commonwealth Equity Services | 36.46 k | $8.00 k |
AMP Ameriprise Financial | 35.00 k | $200.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | J. Kermit Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 1.35 | 12,000 | 16.20 k | 12,000 |
25 Mar 24 | Schuyler Kevin | Stock Option Common Stock | Grant | Acquire A | No | No | 1.35 | 12,000 | 16.20 k | 12,000 |
25 Mar 24 | Tony Goodman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.35 | 42,000 | 56.70 k | 42,000 |
25 Mar 24 | Joseph Truluck | Stock Option Common Stock | Grant | Acquire A | No | No | 1.35 | 25,000 | 33.75 k | 25,000 |
25 Mar 24 | Cary J Claiborne | Stock Option Common Stock | Grant | Acquire A | No | No | 1.35 | 60,000 | 81.00 k | 60,000 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
12 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Apr 24
Press releases
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
10 Apr 24
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
1 Mar 24
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
28 Feb 24
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
15 Feb 24
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
13 Feb 24